Risk factors for unfavorable clinical outcome in patients with documented heparin-induced thrombocytopenia

Thrombosis Research

Volumn 124, Issue 5, 2009, Pages 554-559

  Elalamy, Ismail ^a   Tardy Poncet, Brigitte ^b   Mulot, Agnès ^c   de Maistre, Emmanuel ^d   Pouplard, Claire ^e   Nguyen, Philippe ^f   Cleret, Bénédicte ^g   Gruel, Yves ^e   Lecompte, Thomas ^c   Tardy, Bernard ^b   GEHT HIT study group, ^h  

^a HÔPITAL TENON   (France)

^b UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^c UNIVERSITÉ DE LORRAINE   (France)

^d HÔPITAL DU BOCAGE   (France)

^e UNIVERSITY HOSPITAL OF TOURS   (France)

^f REIMS UNIVERSITY HOSPITAL   (France)

^g Schering Plough Corporation   (France)

^h GEHT TIH: Groupe d'Etude sur l'Hemostase et la Thrombose de la SFH Thrombopenie Induite par l'Hepa

Author keywords

Case control study; Danaparoid; Heparin; Heparin induced thrombocytopenia; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; DANAPAROID; HEPARIN;

ADULT; AGED; AMPUTATION; ARTICLE; BLEEDING; CASE CONTROL STUDY; CONTINUOUS INFUSION; CONTROLLED STUDY; DEATH; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE RESPONSE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PARAMETER; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOCYTE COUNT; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CASE-CONTROL STUDIES; CHONDROITIN SULFATES; DERMATAN SULFATE; HEPARIN; HEPARITIN SULFATE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOCYTOPENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70349983573     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2009.04.002     Document Type: Article

References (23)

1. Arepally G.M., and Ortel T.L. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 355 (2006) 809-817
2. Warkentin T.E., Greinacher A., Koster A., Lincoff A.M., and American College of Chest Physicians. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 6 Suppl (2008) 340S-380S
3. Magnani H.N., and Gallus A. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004. Thromb Haemost 95 (2006) 967-981
4. Silver D., Kapsch D.N., and Tsoi E.K.M. Heparin-induced thrombocytopenia, thombosis and haemorrhage. Ann Surg 198 (1983) 301-306
5. Laster J., Cikrit D., Waler N., and Silver D. The heparin-induced thrombocytopenia syndrome: an update. Surgery 102 (1987) 763-770
6. Almeida J.I., Coats R., Liem T.K., and Silver D. Reduced morbidity and mortality rates of the heparin-induced thrombocytopenia syndrome. J Vasc Surg 27 (1998) 309-316
7. Greinacher A., Farner B., Kroll H., Kohlmann T., Warkentin T.E., and Eichler P. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost 94 (2005) 132-135
8. Lewis B.E., Wallis D.E., Hursting M.J., Levine R.L., and Leya F. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. Chest 129 (2006) 1407-1416
9. Pouplard C., May M.A., Regina S., Marchand M., Fusciardi J., and Gruel Y. Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies. Br J Haematol 128 (2005) 837-841
10. Warkentin T.E., Roberts R.S., Hirsh J., and Kelton J.G. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 163 (2003) 2518-2524
11. Société française d'anesthésie et de reanimation. Thrombopénie induite par l'héparine (Conférence d'expert 2002). Ann Fr Anesth Reanim 22 (2003) 150-159
12. Miettinen O.S. Estimability and estimation in case-referent studies. Am J Epidemiol 103 (1976) 226-235
13. Wan C., Warner M., De Varennes B., Ergina P., Cecere R., and Lachapelle K. Clinical presentation, temporal relationship, and outcome in thirty-three patients with type 2 heparin-induced thrombocytopenia after cardiotomy. Ann Thorac Surg 82 (2006) 21-26
14. Warkentin T.E., and Kelton J.G. A 14-year study of heparin-induced thrombocytopenia. Am J Med 101 (1996) 502-507
15. Kerendi F., Thourani V.H., Puskas J.D., Kilgo P.D., Osgood M., Guyton R.A., et al. Impact of heparin-induced thrombocytopenia on postoperative outcomes after cardiac surgery. Ann Thorac Surg 84 (2007) 1548-1553 discussion 1554-5
16. Lubenow N., Eichler P., Lietz T., Farner B., and Greinacher A. Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies. Blood 104 (2004) 3072-3077
17. Tardy B., Tardy-Poncet B., Fournel P., Venet C., Jospe R., and Dacosta A. Lower limb veins must be systematically explored in patients with isolated heparin-induced thrombocytopenia. Thromb Haemost 82 (1999) 1199-1200
18. Wallis D.E., Workman D.L., Lewis B.E., Steen L., Pifarre R., and Moran J.F. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 106 (1999) 629-635
19. Tardy B., Lecompte T., Boelhen F., Tardy-Poncet B., Elalamy I., Morange P., et al. Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood 108 (2006) 1492-1496
20. LaMonte M.P., Brown P.M., and Hursting M.J. Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy. Crit Care Med 32 (2004) 976-980
21. Opatrny L., and Warner M.N. Risk of thrombosis in patients with malignancy and heparin-induced thrombocytopenia. Am J Hematol 76 (2004) 240-244
22. Hirsh J., Heddle N., and Kelton J.G. Treatment of heparin-induced thrombocytopenia: a critical review. Arch Intern Med 164 (2004) 361-369
23. Farner B., Eichler P., Kroll H., and Greinacher A. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost 85 (2001) 950-957